Hallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy
Abstract
Abstract Dysregulation of the bone marrow (BM) niche in multiple myeloma (MM) alters the composition and state of resident immune cells, potentially impeding antitumor immunity. One common mechanism of immune inhibition in solid tumors is the induction of exhaustion in tumor-specific T cells. However, the extent of T-cell exhaustion is not well characterized in MM. As the specific mechanisms of immune evasion are critical for devising effective therapeutic strategies, we deeply profiled the CD8+ T-cell compartment of patients with newly diagnosed MM (NDMM) for evidence of T-cell activation and exhaustion. We applied single-cell multiomic sequencing and mass cytometry to longitudinal BM and peripheral blood (PB) samples taken from time points spanning from diagnosis to induction therapy, autologous stem cell transplant, and maintenance therapy. We identified an exhausted-like population that lacked several canonical exhaustion markers, was not significantly enriched in patients with NDMM, and consisted of small, nonpersistent clonotypes. We also observed an activated population with increased frequency in the PB of patients with NDMM exhibiting phenotypic and clonal features consistent with homeostatic, cytokine-driven activation. As an orthogonal measurement of T-cell exhaustion, we performed intracellular cytokine staining and found that patients with NDMM lacked functionally exhausted T cells. In summary, there was no evidence of “tumor-experienced” T cells displaying hallmarks of terminal exhaustion and/or antigen-driven activation/expansion in patients with NDMM at any time point.
Article Details
Authors (17)
Carolyn Shasha
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
David R. Glass
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
Ernest Moelhman
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
Laura Islas
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
Yuan Tian
Tony Chour
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
Guoyue Xu
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
Gregory L. Szeto
3Allen Institute for Immunology, Seattle, WA
Tao Peng
Xiaoling Song
3Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, WA
Michelle Wurscher
1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA
Andrew J. Cowan
Thomas F. Bumol
Troy R. Torgerson
Philip D. Greenberg
Damian J. Green
Evan W. Newell
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center